|
IQGAP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.90587999999714E-05 |
| Normal-vs-Stage3 |
1.60316204755873E-13 |
| Normal-vs-Stage4 |
4.38730000107412E-08 |
| Stage1-vs-Stage2 |
2.072200E-02 |
| Stage1-vs-Stage3 |
9.080400E-02 |
| Stage1-vs-Stage4 |
5.061700E-03 |
| Stage2-vs-Stage3 |
1.839870E-03 |
| Stage2-vs-Stage4 |
3.022200E-04 |
| Stage3-vs-Stage4 |
6.543600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.98580000000592E-05 |
| Normal-vs-Asian |
6.2881999607356E-09 |
| Caucasian-vs-AfricanAmerican |
6.891000E-01 |
| Caucasian-vs-Asian |
4.416000E-01 |
| AfricanAmerican-vs-Asian |
3.944600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6269208202857E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.200000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
8.31600011075295E-10 |
| Normal-vs-Age(81-100Yrs) |
3.805600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.923200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.816800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.779020E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.820220E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.565230E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.290400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.279620E-01 |
| Classical-VS-Follicular |
1.11022302462516E-16 |
| Classical-VS-Other |
4.739900E-03 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
2.6988999923816E-09 |
| Tall-VS-Other |
5.643900E-04 |
| Tall-VS-Normal |
1.13450360217371E-11 |
| Follicular-VS-Other |
8.235700E-02 |
| Follicular-VS-Normal |
3.795500E-04 |
| Other-VS-Normal |
1.26280000001255E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.55819998518092E-09 |
| N0-vs-N1 |
6.440500E-03 |
|
|
